Scott Evans, Daniel B Rubin, John H Powers, Dean Follmann
{"title":"Analysis Populations in Anti-Infective Clinical Trials: Whom to Analyze?","authors":"Scott Evans, Daniel B Rubin, John H Powers, Dean Follmann","doi":"10.1515/scid-2017-0002","DOIUrl":null,"url":null,"abstract":"<p><p>Investigators can choose to analyze different patient populations in clinical trials. The different analysis populations answer different types of research questions, estimate different quantities, and evaluate the robustness of the trial results. Various analysis populations have different strengths and weaknesses depending on the type of question being addressed and the potential for bias from the selection of various groups of trial participants. We discuss analysis populations in the context of anti-infective clinical trials.</p>","PeriodicalId":74867,"journal":{"name":"Statistical communications in infectious diseases","volume":"10 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433381/pdf/nihms-988165.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Statistical communications in infectious diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/scid-2017-0002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/8/29 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Investigators can choose to analyze different patient populations in clinical trials. The different analysis populations answer different types of research questions, estimate different quantities, and evaluate the robustness of the trial results. Various analysis populations have different strengths and weaknesses depending on the type of question being addressed and the potential for bias from the selection of various groups of trial participants. We discuss analysis populations in the context of anti-infective clinical trials.